USRM Stock - U.S. Stem Cell, Inc.
Unlock GoAI Insights for USRM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $82,049 | $200,749 | $277,087 | $3.07M | $6.70M |
| Gross Profit | $58,282 | $148,719 | $212,970 | $1.74M | $4.59M |
| Gross Margin | 71.0% | 74.1% | 76.9% | 56.5% | 68.5% |
| Operating Income | $-1,720,484 | $-2,135,858 | $-2,400,241 | $-3,416,856 | $-1,097,903 |
| Net Income | $-2,857,943 | $-3,287,416 | $-2,890,493 | $-3,835,337 | $-2,160,427 |
| Net Margin | -3483.2% | -1637.6% | -1043.2% | -124.8% | -32.2% |
| EPS | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.
Visit WebsiteEarnings History & Surprises
USRMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.00 | — | — |
Q2 2022 | May 23, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q3 2021 | Jul 16, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.00 | — | — |
Q4 2019 | Nov 6, 2019 | — | $-0.00 | — | — |
Q3 2019 | Aug 7, 2019 | — | $-0.00 | — | — |
Q2 2019 | May 7, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.00 | — | — |
Q4 2018 | Nov 7, 2018 | — | $-0.00 | — | — |
Q3 2018 | Aug 8, 2018 | — | $-0.00 | — | — |
Q2 2018 | May 9, 2018 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about USRM
What is USRM's current stock price?
What is the analyst price target for USRM?
What sector is U.S. Stem Cell, Inc. in?
What is USRM's market cap?
Does USRM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to USRM for comparison